“Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials”, J of Skin, vol. 9, no. 1, p. s522, Jan. 2025, doi: 10.25251/skin.9.supp.522.